Connect with us

Psilocybin

PsyCap Recap: 3 Key Takeaways from Mindset Pharma Psychedelic Capital Presentation

The article PsyCap Recap: 3 Key Takeaways from Mindset Pharma Psychedelic Capital Presentation was originally published on Microdose.

The next Psychedelic…

Published

on

The article PsyCap Recap: 3 Key Takeaways from Mindset Pharma Psychedelic Capital Presentation was originally published on Microdose.

The next Psychedelic Capital is just around the corner and we’re featuring, as usual, the most promising psychedelic players with the potential to prevail in this space. You can get your FREE tickets to the next event by clicking this link and/or using the coupon code “recap” (no quotation marks) at check out! We eagerly look forward to seeing you at our next PsyCap conference.

After over a year of our regular Psychedelic Capital conference series, the premiere due diligence conference for the nascent psychedelic medicine sphere, nothing pleases us more than a pioneering psychedelic company returning to share the remarkable progress they have made along in their journey. At our August 2021 Psychedelic Capital event, the team at Mindset Pharma, a valued partner of Microdose, did exactly that. From their mini-yet-informative masterclass put on by Joseph and James that educates investors, clinicians, and science savvy enthusiasts alike, to their fiscal and industry updates, this is a talk you don’t want to miss (and you don’t have to, with recordings). Here are three key takeaways from their most recent PsyCap conference.

Did you happen to miss this talk live at our August 2021 event, not to worry! Do you have FREE Recordings of this Psychedelic Capital event? Click here to get full access to the August PsyCap conference along with full recordings, transcripts, and AI-driven insights! USE CODE: RECAP at purchase for FREE tickets.

Key Takeaway #1: Mindset is Using Medicinal Chemistry, Behavioral Pharmacology, & Hard Science to Guide the Development of the Next Generation of Psychedelic Medicine

Many of the traditional psychedelic compounds that have currently been proceeding through the clinical trial pipeline, despite showing strong efficacy and safety profiles, have been around for at least several decades if not hundreds of years or more. However, just because the traditional psychedelic drugs are older, each with their various advantages and disadvantages concerning safety and efficacy doesn’t mean we can’t combine our knowledge of the current psychopharmacology of these compounds with cutting-edge advancement in biotechnology and drug development technologies. Indeed, that is the exact mission of the Mindset Pharma team, who are employing everything from medicinal chemistry, behavioral pharmacology, and hard science to back up their drug development plays. To the team at Mindset, nature is an optimal starting point to discover new drugs, but it is the combination and applications of naturally occurring psychedelics (or molecules that are inspired by them) with the most cutting-edge drug development techniques that’ll help produce the next generation of effective psychedelic medication.

Key Takeaway #2: Mindset Pharma’s Lead Drug Candidate, MSP1014, Is Inspired by Psilocybin but has Some Major Advantages

Psilocybin has undoubtedly been something of a rockstar in the modern psychedelic movement. Indeed, the clinical data coming out of world-class research institutions supports its use for a variety of applications in the treatment of mental illness. Through careful consideration, Mindset Pharma has decided to pursue MSP 1014 due to its having several benefits of traditional psilocybin. Indeed, the rationale for that is there was a good amount of clinical data available for psilocybin, showing promise and things like treatment-resistant depression and substance abuse. The team looked at several different chemistry approaches to achieve novelty with these analogs, things like deuteration, prodrugs, conjugation, and lot halogenation, which ultimately led the team to select MSP 1014.

Key Takeaway #3: Mindset Pharma is Paying Close Attention to Safety in their Drug Development

While psychedelics, by and large, have an established safety profile, there are still some important safety concerns to consider, such as serotonin syndrome. Since these compounds have been used for a long time, but not necessarily in large numbers of people in different types of people with different genetic makeups, the team intends to conduct more studies to evaluate its efficacy in larger groups of people. The team will be determining the optimal dose and being able to demonstrate that one can separate some of the safety concerns from what might be some of the hallucinogenic benefits will be an important way forward.

Closing Thoughts & Looking Ahead for Mindset Pharma

The Mindset Pharma team came back to give a fascinating update on the remarkable progress they’ve made since their last PsyCap presentation. From using the most advanced drug delivery methods, such as medicinal chemistry and behavioral pharmacology, to their new drug candidate, MSP 1014, in the psilocybin family, the Mindset Team is certainly making great strides.

Read More

Trending